Patents by Inventor James Gail Christensen

James Gail Christensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPIES
    Publication number: 20220040182
    Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a mTOR inhibitor and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.
    Type: Application
    Filed: September 10, 2019
    Publication date: February 10, 2022
    Inventors: Peter Olson, Ruth Wei Aranda, James Gail Christensen, Lars Daniel Engstrom, Jill Hallin
  • Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
    Patent number: 11220509
    Abstract: The present disclosure relates to compounds of Formula (I), or pharmaceutically, acceptable salts thereof, that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present disclosure relates to compounds, or pharmaceutically acceptable salts thereof pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising compounds of Formula (I), or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: January 11, 2022
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Matthew Arnold Marx, Matthew Randolph Lee, Thomas P. Bobinski, Aaron Craig Burns, Nidhi Arora, James Gail Christensen, John Michael Ketcham
  • KRAS G12C INHIBITORS
    Publication number: 20210269432
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: May 17, 2017
    Publication date: September 2, 2021
    Applicants: Mirati Therapeutics, Inc., Array BioPharma Inc.
    Inventors: John P. FISCHER, Jay Bradford FELL, James F. BLAKE, Ronald Jay HINKLIN, Macedonio J. MEJIA, Erik James HICKEN, Mark Joseph CHICARELLI, John J. GAUDINO, Guy P.A. VIGERS, Laurence E. BURGESS, Matthew Arnold MARX, James Gail CHRISTENSEN, Matthew Randolf LEE, Pavel SAVECHENKOV, Henry J. ZECCA, Tony P. TANG
  • Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
    Patent number: 11091495
    Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds of Formula (I) and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: August 17, 2021
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Matthew Arnold Marx, Matthew Randolph Lee, Thomas P. Bobinski, Aaron Craig Burns, Nidhi Arora, James Gail Christensen, John Michael Ketcham
  • PRC2 INHIBITORS
    Publication number: 20210230168
    Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: March 31, 2021
    Publication date: July 29, 2021
    Inventors: Matthew Arnold MARX, Matthew Randolph LEE, Thomas P. BOBINSKI, Aaron Craig BURNS, Nidhi ARORA, James Gail CHRISTENSEN, John Michael KETCHAM
  • PRC2 INHIBITORS
    Publication number: 20210101904
    Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: December 9, 2020
    Publication date: April 8, 2021
    Inventors: Matthew Arnold MARX, Matthew Randolph LEE, Thomas P. BOBINSKI, Aaron Craig BURNS, Nidhi ARORA, James Gail CHRISTENSEN, John Michael KETCHAM
  • COMBINATION THERAPIES
    Publication number: 20210085683
    Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a an agent that blocks Programmed Death-1 receptor (PD-1) and Programmed Death Ligand-1 (PD-L1) signaling and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, kits comprising the compositions and methods of use therefor.
    Type: Application
    Filed: September 23, 2020
    Publication date: March 25, 2021
    Inventors: David Briere, James Gail Christensen, Pete Olson
  • PRC2 Inhibitors
    Publication number: 20210032252
    Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: January 29, 2019
    Publication date: February 4, 2021
    Inventors: Matthew Arnold Marx, Matthew Randolph Lee, Thomas P. Bobinski, Aaron Craig Burns, Nidhi Arora, James Gail Christensen, John Michael Ketcham
  • KRAS G12C INHIBITORS
    Publication number: 20200331911
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: June 30, 2020
    Publication date: October 22, 2020
    Inventors: Matthew Arnold Marx, James Gail Christensen, Christopher Ronald Smith, John P. Fischer, Aaron Craig Burns
  • KRas G12C inhibitors
    Patent number: 10689377
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: June 23, 2020
    Assignees: Mirati Therapeutics, Inc., Array Biopharma Inc.
    Inventors: James F. Blake, Laurence E. Burgess, Mark Joseph Chicarelli, James Gail Christensen, Adam Cook, Jay Bradford Fell, John P. Fischer, Matthew Arnold Marx, Macedonio J. Mejia, Pavel Savechenkov, Guy P. A. Vigers, Christopher Ronald Smith, Martha E. Rodriguez
  • KRas G12C inhibitors
    Patent number: 10633381
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: April 28, 2020
    Assignees: Mirati Therapeutics, Inc., Array BioPharma Inc.
    Inventors: James F. Blake, Laurence E. Burgess, Mark Joseph Chicarelli, James Gail Christensen, Jay Bradford Fell, John P. Fischer, John J. Gaudino, Erik James Hicken, Ronald Jay Hinklin, Matthew Randolf Lee, Matthew Arnold Marx, Macedonio J. Mejia, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P. A. Vigers, Henry J. Zecca
  • KRAS G12C INHIBITORS
    Publication number: 20190144444
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: November 14, 2018
    Publication date: May 16, 2019
    Inventors: James F. Blake, Laurence E. Burgess, Mark Joseph Chicarelli, James Gail Christensen, Adam Cook, Jay Bradford Fell, John P. Fischer, Matthew Arnold Marx, Macedonio J. Mejia, Pavel Savechenkov, Guy P.A. Vigers, Christopher Ronald Smith, Martha E. Rodriguez
  • LSD1 inhibitors
    Patent number: 10233152
    Abstract: The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: March 19, 2019
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Matthew Arnold Marx, Arkadii Vaisburg, James Gail Christensen, Robert Anthony Galemmo, Jr.
  • KRAS G12C INHIBITORS
    Publication number: 20190062330
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: October 29, 2018
    Publication date: February 28, 2019
    Inventors: James F. Blake, Laurence E. Burgess, Mark Joseph Chicarelli, James Gail Christensen, Jay Bradford Fell, John P. Fischer, John J. Gaudino, Erik James Hicken, Ronald Jay Hinklin, Matthew Randolf Lee, Matthew Arnold Marx, Macedonio J. Mejia, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Henry J. Zecca
  • KRas G12C inhibitors
    Patent number: 10125134
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: November 13, 2018
    Assignees: MIRATI THERAPEUTICS, INC., ARRAY BIOPHARMA INC.
    Inventors: James F. Blake, Laurence E. Burgess, Mark Joseph Chicarelli, James Gail Christensen, Jay Bradford Fell, John P. Fischer, John J. Gaudino, Erik James Hicken, Ronald Jay Hinklin, Matthew Randolf Lee, Matthew Arnold Marx, Macedonio J. Mejia, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P. A. Vigers, Henry J. Zecca
  • LSD1 Inhibitors
    Publication number: 20180127369
    Abstract: The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: October 5, 2017
    Publication date: May 10, 2018
    Inventors: Matthew Arnold Marx, Arkadii Vaisburg, James Gail Christensen, Robert Anthony Galemmo, JR.
  • KRAS G12C INHIBITORS
    Publication number: 20180072723
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: November 15, 2017
    Publication date: March 15, 2018
    Inventors: James F. Blake, Laurence E. Burgess, Mark Joseph Chicarelli, James Gail Christensen, Jay Bradford Fell, John P. Fischer, John J. Gaudino, Erik James Hicken, Ronald Jay Hinklin, Matthew Randolf Lee, Matthew Arnold Marx, Macedonio J. Mejia, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Henry J. Zecca
  • LSD1 inhibitors
    Patent number: 9809541
    Abstract: The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: November 7, 2017
    Assignee: Mirati Therapeutics, Inc.
    Inventors: Matthew Arnold Marx, Arkadii Vaisburg, James Gail Christensen, Robert Anthony Galemmo, Jr.
  • LSD1 Inhibitors
    Publication number: 20170183308
    Abstract: The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: November 3, 2016
    Publication date: June 29, 2017
    Applicant: Mirati Therapeutics, Inc.
    Inventors: Matthew Arnold Marx, Arkadii Vaisburg, James Gail Christensen, Robert Anthony Galemmo, JR.
  • CRIZOTINIB FOR USE IN THE TREATMENT OF CANCER
    Publication number: 20160206608
    Abstract: The present invention relates to the use of ROS kinase inhibitors for treating abnormal cell growth in mammals. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ROS. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ROS by administration of crizotinib.
    Type: Application
    Filed: July 24, 2012
    Publication date: July 21, 2016
    Applicant: Pfizer Inc.
    Inventors: James Gail Christensen, Yahong Zou